<doc>
  <docmeta id="113hr4250ih">
    <bill congress="113" type="hr" number="4250" version="ih"/>
    <revision size="31959" annotations="0" status="complete" id="5" commit-time="2014-04-01T21:30:27Z" committer="mbohmer" doc="113hr4250ih/5.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H507337563DF34F068FCC6B063FA5ABA8" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 4250 IH: Sunscreen Innovation Act</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-03-13</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4250</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140313">March 13, 2014</action-date>
			<action-desc>
        <sponsor name-id="W000413">Mr. Whitfield</sponsor> (for himself and <cosponsor name-id="D000355">Mr. Dingell</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to provide an alternative process for review of
			 safety and effectiveness of nonprescription sunscreen active ingredients
			 and for other purposes.</official-title>
	</form>
	<legis-body id="H73122D2FA0EA49379368B76998F88E88" style="OLC">
		<section id="H3B5EBFE64CEA42358C6EF161DA0B8955" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">
            <short-title>Sunscreen Innovation Act</short-title>
          </cato:entity-ref>
        </quote>.</text>
		</section>
    <section id="HC746E5539E9841F69275E65CA66B1B31">
      <enum>2.</enum>
      <header>Regulation of nonprescription sunscreen active ingredients</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:A">Subchapter A of chapter V</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/351">
          <cato:entity-ref entity-type="uscode" value="usc/21/351/etseq">21 U.S.C. 351 et seq</cato:entity-ref>.</external-xref>)</cato:entity> is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H2688DD524DFF47A98804B1A584474E29" style="OLC">
				<section id="H93650B9566274A268282FA071411CF0D">
          <enum>524B.</enum>
          <header>Procedures for classifying sunscreen active ingredients</header>
					<subsection commented="no" id="HAE03FADC67FD490A9817D5393ED10876">
            <enum>(a)</enum>
            <header>In general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall review and determine whether nonprescription sunscreen conditions are generally
			 recognized as safe and effective and shall ensure that any such conditions
			 that are marketed in the United States are appropriately labeled.</text>
					</subsection>
          <subsection id="HD55792882FA84D4D8D531A61BE454A16">
            <enum>(b)</enum>
            <header>Definitions</header>
						<paragraph id="H5650E08733504B19B828121BE9F9A208">
              <enum>(1)</enum>
              <header>Active ingredient</header>
              <text>The term <term>active ingredient</term> means any component that is intended to furnish pharmacological activity or other direct effect in
			 the diagnosis, cure, mitigation, treatment, or prevention of disease, or
			 to affect the structure or function of the body of humans or animals. The
			 term includes components that may undergo chemical change in the
			 manufacture of a drug and may be present in a drug in a modified form
			 intended to furnish the specified activity or effect.</text>
						</paragraph>
            <paragraph id="H143CD09906C540909EFA6746DDCDBE10">
              <enum>(2)</enum>
              <header>Sunscreen active ingredient</header>
              <text>The term <term>sunscreen active ingredient</term> means an active ingredient that absorbs, reflects, or scatters radiation in the ultraviolet range
			 at wavelengths from 290 to 400 nanometers.</text>
						</paragraph>
            <paragraph id="HF4E515D7FE0C41EEBB7A6C487F1C0503">
              <enum>(3)</enum>
              <header>Sunscreen condition</header>
              <text>The term <term>sunscreen condition</term> means a sunscreen active ingredient (or a combination of sunscreen active ingredients), dosage
			 form, dosage strength, or route of administration, marketed for a specific
			 nonprescription use.</text>
						</paragraph>
          </subsection>
          <subsection commented="no" id="H6B8A3286662342E1B680074CC5D2B634">
            <enum>(c)</enum>
            <header>Criteria for eligibility</header>
            <text>To be eligible for review under this section, a sunscreen condition shall—</text>
						<paragraph commented="no" id="HC65459CCDEE9495A814C02C2E4E85D31">
              <enum>(1)</enum>
              <text>not be included in the stayed sunscreen monograph; and</text>
						</paragraph>
            <paragraph commented="no" id="HC5697CD824C54E99924E9F6218594B44">
              <enum>(2)</enum>
              <text>have been marketed as a nonprescription sunscreen condition in the United States or at least 1
			 other country, or marketed as a cosmetic or dietary supplement in 1 or
			 more counties other than the United States—</text>
							<subparagraph commented="no" id="H9C4501113F684C6991AC55628B012D26">
                <enum>(A)</enum>
                <text>for a minimum of 5 continuous years; and</text>
							</subparagraph>
              <subparagraph commented="no" id="HD3EB7F67892047BDA483690ED44D8790">
                <enum>(B)</enum>
                <text>in sufficient quantity, as determined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> based upon the information submitted under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:1/sp:D" proposed="true">subparagraphs (D)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:1/sp:E" proposed="true">(E) of subsection (d)(1)</cato:entity-ref> and, if applicable,
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:A/cl:ii" proposed="true">subsection (d)(2)(A)(ii)</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <subsection id="H464C124CB7CE4C87BD2AC3A8EF6380F3">
            <enum>(d)</enum>
            <header>Application for eligibility</header>
						<paragraph id="H21B8ED4380DF459ABE39C065D34D5097">
              <enum>(1)</enum>
              <header>In general</header>
              <text>A sponsor of a nonprescription sunscreen condition described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:c" proposed="true">subsection (c)</cato:entity-ref> desiring to market
			 such condition in the United States may submit an application to the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in such manner and containing such information as required by
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, including the following:</text>
							<subparagraph id="H6DD1F929A7AA4BD0AFAF1C47B122F913">
                <enum>(A)</enum>
                <text>Basic information about the sunscreen condition (including a description of each active ingredient,
			 pharmacologic class, intended nonprescription use, nonprescription
			 strength and dosage form, route of administration, and directions for
			 use).</text>
							</subparagraph>
              <subparagraph id="H6C92A242A4B04617BE2C996F4990F7D4">
                <enum>(B)</enum>
                <text>A detailed chemical description of the sunscreen active ingredient that includes a full description
			 of the drug substance, including its physical and chemical
			 characteristics, the method of synthesis (or isolation) and purification
			 of the drug substance, and any specifications and analytical methods
			 necessary to ensure the identity, strength, quality, and purity of the
			 drug substance, including reference to the current edition of the official
			 National Formulary, the United States Pharmacopeia, or foreign
			 compendiums, where applicable.</text>
							</subparagraph>
              <subparagraph id="H43442DC6DFB84A7EB5ECC943924B92B8">
                <enum>(C)</enum>
                <text>A list of each country in which the sunscreen condition has been marketed.</text>
							</subparagraph>
              <subparagraph id="H5E854F8A7FE34009959182A23526B153">
                <enum>(D)</enum>
                <text>The cumulative total number of dosage units sold for each dosage form of the sunscreen condition,
			 including total weight of the active ingredient, package size for each
			 dosage form in which the condition is marketed as nonprescription, and an
			 estimate of the minimum number of potential consumer exposures to the
			 condition.</text>
							</subparagraph>
              <subparagraph id="H6E424D36366C494691D373A77A96CC5A">
                <enum>(E)</enum>
                <text>The use pattern (according to the label) for each country in which the sunscreen condition is
			 marketed and any changes in use pattern that have occurred over time.</text>
							</subparagraph>
              <subparagraph id="H220F4FB166264AB2A2A7DFB3253813D5">
                <enum>(F)</enum>
                <text>A list of all countries in which the sunscreen condition has been withdrawn from marketing or in
			 which an application for nonprescription marketing approval has been
			 denied and an explanation for such withdrawal or application denial.</text>
							</subparagraph>
            </paragraph>
            <paragraph commented="no" id="HC96A2C2DD9404A438CD34423C13FF254">
              <enum>(2)</enum>
              <header>Sunscreen conditions that have not been marketed in the United States for 5 continuous years</header>
							<subparagraph commented="no" id="H65E0BDB028A94D579A37D111E4792316">
                <enum>(A)</enum>
                <header>In general</header>
                <text>In the case of an application with respect to a nonprescription sunscreen condition that has not
			 been marketed in the United States for 5 continuous years, in addition to
			 the information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:1" proposed="true">paragraph (1)</cato:entity-ref>, the sponsor shall submit the
			 following information for each country in which the sunscreen condition
			 has been marketed:</text>
								<clause id="H5B091AAACF2C46AF855E203FFCB8CF4A">
                  <enum>(i)</enum>
                  <text>The manner in which the sunscreen condition has been marketed to consumers. If the sunscreen
			 condition is marketed to consumers as a nonprescription pharmacy only
			 condition, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may require supplemental information.</text>
								</clause>
                <clause commented="no" id="HE51F08F71B3F4F2785BB14B7739EDDD3">
                  <enum>(ii)</enum>
                  <text>A description of the population demographics and the source from which this information has been
			 compiled, to ensure that the sunscreen condition's use can be reasonably
			 extrapolated to the population of the United States.</text>
								</clause>
                <clause id="HD9B718C8506948368A804F68A29546D6">
                  <enum>(iii)</enum>
                  <text>A description of the country’s system for identifying adverse drug experiences, especially those
			 found in nonprescription marketing experience, including method of
			 collection if applicable.</text>
								</clause>
                <clause id="HA986A0935A1340DAAAD75428A7D40113">
                  <enum>(iv)</enum>
                  <text>A statement of how long the sunscreen condition has been marketed in each country and how long the
			 current product labeling has been in use, accompanied by a copy of the
			 current product labeling, including a translation into English of any
			 labeling that is not in English, and a statement of whether the current
			 product labeling has been authorized, accepted, or approved by a
			 regulatory body in each country where the condition is marketed.</text>
								</clause>
                <clause id="H4D196654AFBE4633B16EFF859E800970">
                  <enum>(v)</enum>
                  <text>A list of all countries where the sunscreen condition is marketed as a prescription drug only and
			 an explanation for such restriction.</text>
								</clause>
              </subparagraph>
              <subparagraph id="HE725A2BA1B0B49889004FFA07968FA50">
                <enum>(B)</enum>
                <header>Sunscreen conditions that have been marketed in more than 5 countries</header>
								<clause id="H89C77381EF8D49679DA48CD4C7EA7CE8">
                  <enum>(i)</enum>
                  <header>In general</header>
                  <text>In the case of a sunscreen condition that has been marketed as a nonprescription sunscreen in more
			 than 5 countries, with a minimum of 5 continuous years of marketing in at
			 least one such country, the sponsor—</text>
									<subclause id="HE43CC9AED3E84D80A69F007EA8772CFD">
                    <enum>(I)</enum>
                    <text>may submit information in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:A/cl:i..iv" proposed="true">clauses (i) through (iv) of subparagraph (A)</cato:entity-ref> with respect
			 to only 5 such countries, including—</text>
										<item id="H9E696842C1A1485E830205F50DA1CDCC">
                      <enum>(aa)</enum>
                      <text>the country with a minimum of 5 continuous years of nonprescription marketing;</text>
										</item>
                    <item id="H3A5F160763DA43D8B746A0A16C712BBA">
                      <enum>(bb)</enum>
                      <text>the country with the longest duration of marketing; and</text>
										</item>
                    <item id="H6FB9BE6D5283434EB138349510BEEDD1">
                      <enum>(cc)</enum>
                      <text>the country with the most support for marketing, such as a large volume of sales with cultural
			 diversity among users of the product; and</text>
										</item>
                  </subclause>
                  <subclause id="H03AE723AB3424DDDB9F69D5CAE42300F">
                    <enum>(II)</enum>
                    <text>shall explain the basis for the countries selected under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:B/cl:i/scl:I" proposed="true">subclause (I)</cato:entity-ref>; and</text>
									</subclause>
                  <subclause id="HBA247F04534C4C95AE3CAA7C1A40B0EB">
                    <enum>(III)</enum>
                    <text>shall provide information from more than 5 countries if such information is needed to support the
			 application.</text>
									</subclause>
                </clause>
                <clause id="H9F54EFC2601540E79B1387884DA4BE0B">
                  <enum>(ii)</enum>
                  <header>Requirement</header>
                  <text>If the sunscreen condition meets the criteria under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:B/cl:i/scl:I/i:aa..cc" proposed="true">items (aa) through (cc) of clause (i)(I)</cato:entity-ref> in 1
			 or more countries listed in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:802/ss:b/p:1/sp:A">section 802(b)(1)(A)</cato:entity-ref>, at least 1 such country
			 shall be included among the 5 countries selected under such <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d/p:2/sp:B/cl:i/scl:I" proposed="true">clause (i)(I)</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
            </paragraph>
            <paragraph commented="no" id="HD54B2DD758CF4D4083D10E7815DDA146">
              <enum>(3)</enum>
              <header>Pending applications</header>
              <text>The requirements of this subsection shall not apply to a sunscreen condition deemed eligible for
			 review of safety and effectiveness by publication of a notice of
			 eligibility in the Federal Register prior to the date of enactment of the <short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation Act</cato:entity-ref>
                </short-title>. Applications for such sunscreen conditions shall be considered in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:g" proposed="true">subsection (g)</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection commented="no" id="H06FC9AC3947A42C3B882511F7C792707">
            <enum>(e)</enum>
            <header>Public availability</header>
            <text>If a condition is found eligible under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d" proposed="true">subsection (d)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make the application
			 publicly available, with redactions for confidential commercial
			 information or trade secret information, and any other information exempt
			 from disclosure pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1905">
                <external-xref legal-doc="usc" parsable-cite="usc/18/1905">section 1905</external-xref> of title 18, United States Code</cato:entity-ref>,
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/552/b">
                <external-xref legal-doc="usc" parsable-cite="usc/5/552">section 552(b)</external-xref> of title 5, United States Code</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:j">section 301(j) of this
			 Act</cato:entity-ref>. Applications shall remain confidential during the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary's</cato:entity-ref>
			 consideration of eligibility.</text>
					</subsection>
          <subsection id="H332B1070B33042849C91BCA824EF8449">
            <enum>(f)</enum>
            <header>New sunscreen condition application</header>
						<paragraph id="HFFF31AE6643642AE8989BDA26976B0B7">
              <enum>(1)</enum>
              <header>Eligibility determination</header>
              <text>Not later than 60 days after the submission of an eligibility application under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:d" proposed="true">subsection (d)</cato:entity-ref>, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall determine if the sunscreen condition is eligible for
			 further review for safety and effectiveness. In the case of a sunscreen
			 condition determined to be eligible, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish a notice
			 of eligibility in the Federal Register, and provide interested persons an
			 opportunity to submit published and unpublished data related to the safety
			 and effectiveness of the sunscreen condition for its intended
			 nonprescription uses, in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">paragraph (2)</cato:entity-ref>. In the case of a
			 sunscreen condition determined not eligible, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a
			 letter to the sponsor, which shall be made publicly available.</text>
						</paragraph>
            <paragraph id="H20C2A0276BB04588BDEFBD24F8238494">
              <enum>(2)</enum>
              <header>Safety and effectiveness data submissions</header>
							<subparagraph id="H88D7C30DAD784745B15B57FB80D2BB7D">
                <enum>(A)</enum>
                <header>In general</header>
                <text>Within 60 days of the publication in the Federal Register of an application deemed eligible, as
			 described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:1" proposed="true">paragraph (1)</cato:entity-ref>, the sponsor and other interested parties shall
			 submit safety and effectiveness data to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for further review,
			 as described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>.</text>
							</subparagraph>
              <subparagraph id="H178623673B4240FC8640CCB4F604E5D3">
                <enum>(B)</enum>
                <header>Required submissions regarding data</header>
                <text>Submissions under this paragraph shall include the following:</text>
								<clause id="H33AD9E096D004B65AF4E021D464BA836">
                  <enum>(i)</enum>
                  <header>Human safety data</header>
									<subclause id="H790F8F1AC0244F7D8CAD58B3F5F78312">
                    <enum>(I)</enum>
                    <header>Individual active components</header>
                    <text>With respect to individual active components, controlled studies, partially controlled or
			 uncontrolled studies, documented case reports, pertinent marketing
			 experiences that may influence a determination as to the safety of each
			 individual active component, and pertinent medical and scientific
			 literature.</text>
									</subclause>
                  <subclause id="H7FA37FCD3DA241C193EF418B3CA43414">
                    <enum>(II)</enum>
                    <header>Combinations of individual active components</header>
                    <text>With respect to combinations of the individual active components, controlled studies,
			 partially controlled or uncontrolled studies, documented case reports,
			 pertinent marketing experiences that may influence a determination as to
			 the safety of combinations of the individual active component, and
			 pertinent medical and scientific literature.</text>
									</subclause>
                </clause>
                <clause id="HE19FC4DC612F49A1B9B67FBFFA78A43D">
                  <enum>(ii)</enum>
                  <header>Efficacy data</header>
									<subclause id="H3C25EA7AC3F8425BBD6CB7BC0D795D3B">
                    <enum>(I)</enum>
                    <header>Individual active components</header>
                    <text>With respect to individual active components, controlled studies, partially controlled or
			 uncontrolled studies, documented case reports, pertinent marketing
			 experiences that may influence a determination on the efficacy of each
			 individual active component, pertinent medical and scientific literature.</text>
									</subclause>
                  <subclause id="H5843979749BA45EBB722EB24E7E90B34">
                    <enum>(II)</enum>
                    <header>Combinations of individual active components</header>
                    <text>With respect to combinations of the individual active components, controlled studies,
			 partially controlled or uncontrolled studies, documented case reports,
			 pertinent marketing experiences that may influence a determination on the
			 efficacy of combinations of the individual active components, and
			 pertinent medical and scientific literature.</text>
									</subclause>
                </clause>
                <clause id="H4F60F67779704A9291EF3AF4809A07D5">
                  <enum>(iii)</enum>
                  <header>Data setting forth medical rationale and purpose</header>
                  <text>A summary of the data and views setting forth the medical rationale and purpose (or lack thereof)
			 for the sunscreen condition and the scientific basis (or lack thereof) for
			 the conclusion that the condition has been proven safe and effective for
			 the intended use. If there is an absence of controlled studies in the
			 material submitted, an explanation as to why such studies are not
			 considered necessary must be included.</text>
								</clause>
                <clause id="H58E6EF058A5F40108D17C692C45636A8">
                  <enum>(iv)</enum>
                  <header>Official drug monograph</header>
                  <text>An applicable United States Pharmacopoeia or National Formulary for the sunscreen active ingredient
			 or a proposed standard for inclusion in an article to be recognized in an
			 official drug monograph for the active ingredient, including information
			 showing that the official or proposed compendial monograph for the active
			 ingredient is consistent with the active ingredient used in the studies
			 establishing safety and effectiveness and with the active ingredient
			 marketed in the nonprescription product to a material extent and for a
			 material time. If differences exist between the official or proposed
			 compendial monograph for the active ingredient and the active ingredient
			 that is the subject of the application, sponsor shall explain such
			 differences.</text>
								</clause>
                <clause id="HA954D9586CBF4F79B08F0788A5974426">
                  <enum>(v)</enum>
                  <header>Adverse drug experiences</header>
                  <text>A list of all serious adverse drug experiences, as defined by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, from each country
			 where the condition has been or is currently marketed as a prescription
			 drug or as a nonprescription drug or product.</text>
								</clause>
              </subparagraph>
              <subparagraph id="H639021AA0AA345BFBE6B83A5E91D0AE6">
                <enum>(C)</enum>
                <header>Optional animal safety data</header>
                <text>In addition to the information required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2/sp:B" proposed="true">subparagraph (B)</cato:entity-ref>,  the  sponsor may submit
			 information with
			 respect to animal safety data, including controlled studies and partially
			 controlled or uncontrolled studies, in the case of an application for
			 individual active components, and controlled studies and partially
			 controlled or uncontrolled studies in the case of an application for
			 combinations of individual active components.</text>
							</subparagraph>
              <subparagraph commented="no" id="H5657BC4199D94411B0213E0C57CD8560">
                <enum>(D)</enum>
                <header>Confidentiality of submissions</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make data and information submitted by the sponsor, or pursuant to a notice
			 requesting safety and effectiveness data published in the Federal
			 Register, publicly available, with redactions for confidential commercial
			 information or trade secret information, and any other information exempt
			 from disclosure pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/18/1905">
                    <external-xref legal-doc="usc" parsable-cite="usc/18/1905">section 1905</external-xref> of title 18, United States Code</cato:entity-ref>,
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/552/b">
                    <external-xref legal-doc="usc" parsable-cite="usc/5/552">section 552(b)</external-xref> of title 5, United States Code</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:j">section 301(j) of this
			 Act</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H9CDA14BC51044CE8800149B3D78FDF27">
              <enum>(3)</enum>
              <header>New sunscreen condition application submission to the advisory committee</header>
              <text>Not later than 30 days after the end of the public comment period described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">paragraph (2)</cato:entity-ref>, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit the application and the safety and effectiveness
			 data submitted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">paragraph (2)</cato:entity-ref> to the Nonprescription Drugs Advisory
			 Committee (referred to in this section as the <quote>advisory committee</quote>) for review.</text>
						</paragraph>
          </subsection>
          <subsection id="H5382F2DE712543B7AB2E06CFD84243E6">
            <enum>(g)</enum>
            <header>Pending sunscreen condition applications</header>
            <text>Not later than 30 days after the date of enactment of the <short-title>
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation Act</cato:entity-ref>
              </short-title>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall submit to the advisory committee all safety and effectiveness data submitted
			 with respect to each application for review of sunscreen conditions that
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> had determined, prior to the date of enactment of the <short-title>
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation Act</cato:entity-ref>
              </short-title>, to be eligible for review of safety and effectiveness and for which the information required
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">subsection (f)(2)</cato:entity-ref> has been submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> prior to such
			 date of enactment.</text>
					</subsection>
          <subsection id="H2B031DA6CC904392B6D47D8022975A17">
            <enum>(h)</enum>
            <header>Review and recommendation for nonprescription sunscreen condition</header>
						<paragraph id="H9617F4DD2BBF4AA08D2CB04DF3601E83">
              <enum>(1)</enum>
              <header>In general</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall require the advisory committee to evaluate the safety and effectiveness data
			 submitted in accordance with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:2" proposed="true">subsection (f)(2)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:g" proposed="true">(g)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="H59EE53E5A2F14A9880CABDC9A6B4B6F3">
              <enum>(2)</enum>
              <header>Standards</header>
              <text>In evaluating a nonprescription sunscreen condition under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:1" proposed="true">paragraph (1)</cato:entity-ref>, the advisory committee
			 shall use the regulations in effect at the time of the application,
			 including regulations with respect to—</text>
							<subparagraph id="HE5090E4A810E472DBDB9D5B2AF23FAAE">
                <enum>(A)</enum>
                <text>the safety of the nonprescription sunscreen condition;</text>
							</subparagraph>
              <subparagraph id="HF23EB077694349678F53D641BBDB9C32">
                <enum>(B)</enum>
                <text>the effectiveness of the nonprescription sunscreen condition;</text>
							</subparagraph>
              <subparagraph id="H86AE734A1F8C4942B0747F946E246861">
                <enum>(C)</enum>
                <text>the benefit-to-risk ratio of the nonprescription sunscreen condition; and</text>
							</subparagraph>
              <subparagraph id="HC017E7BD2A814D97AB9FB8D926A469DD">
                <enum>(D)</enum>
                <text>the labeling of the nonprescription sunscreen condition.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H2D2B62BB5756404D84912F05DE20D2B9">
              <enum>(3)</enum>
              <header>Communications between advisory committee and other individuals who submit data</header>
              <text>The advisory committee shall have the authority to communicate with the sponsor and other
			 individuals who submit data during the advisory committee's review,
			 including requesting clarification or additional information.</text>
						</paragraph>
            <paragraph id="H91A8A73C183B4277A166667412929C37">
              <enum>(4)</enum>
              <header>Recommendations</header>
							<subparagraph id="H0E09A45187C748FEB7F878456F33C847">
                <enum>(A)</enum>
                <header>In general</header>
                <text>For each such submission under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:3" proposed="true">subsection (f)(3)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:g" proposed="true">(g)</cato:entity-ref>, the advisory committee shall make one of
			 the following recommendations to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>:</text>
								<clause id="HD713DB3AA6E44B6CA61A7B232A2E2504">
                  <enum>(i)</enum>
                  <text>The sunscreen condition is generally recognized as safe and effective (including any or all
			 indications), including nonprescription sunscreen conditions for which a
			 new drug application has been approved by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
								</clause>
                <clause id="HD03E1FA4435C4AE28726ACD77A9CD61B">
                  <enum>(ii)</enum>
                  <text>Insufficient information has been provided to support a recommendation that the sunscreen condition
			 is generally recognized as safe and effective (including any or all
			 indications).</text>
								</clause>
                <clause id="HEFD25DE178F44A968AA0BADD0025050B">
                  <enum>(iii)</enum>
                  <text>The sunscreen condition is not generally recognized as safe and effective to be marketed or sold
			 unless an application with respect to such condition is approved under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
              <subparagraph commented="no" id="H83D6582A4F074B9E836D22F7125B787A">
                <enum>(B)</enum>
                <header>Timing</header>
                <text>The advisory committee shall make a recommendation under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> not later than 180 days
			 after the advisory committee receives the application and data submitted
			 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:f/p:3" proposed="true">subsection (f)(3)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:g" proposed="true">subsection (g)</cato:entity-ref>.</text>
							</subparagraph>
              <subparagraph commented="no" id="H992CC0118F3C419F9DF2CE6AEE593EE0">
                <enum>(C)</enum>
                <header>Resubmission of data</header>
                <text>If the advisory committee recommends that insufficient information has been provided, in accordance
			 with <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A/cl:ii" proposed="true">subparagraph (A)(ii)</cato:entity-ref>, the advisory committee shall make such
			 recommendation not later than 180 days after the date on which such
			 additional information is submitted.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <subsection id="H5BDBCB398CC24A3C8FF447C987C5CE21">
            <enum>(i)</enum>
            <header>Determination by the Center for Drug Evaluation and Research</header>
						<paragraph id="H40A43702B03D4709858C0AC3DE448E8D">
              <enum>(1)</enum>
              <header>In general</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref> shall respond to the recommendations of the advisory
			 committee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4" proposed="true">subsection (h)(4)</cato:entity-ref> as follows:</text>
							<subparagraph id="H9B67D63D51794EACA697DB6685EC7187">
                <enum>(A)</enum>
                <text>In the case of a recommendation by the advisory committee described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A/cl:i" proposed="true">clause (i) of subsection
			 (h)(4)</cato:entity-ref>, not later than 45 days after the advisory committee issues the
			 recommendation, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref> shall issue a
			 determination affirming or denying the recommendation of the advisory
			 committee. If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref> affirms the
			 recommendation of the advisory committee, or if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug
			 Evaluation and Research</cato:entity-ref> takes no action regarding the recommendation
			 within 45 days of receiving such recommendation, the nonprescription
			 sunscreen condition shall be generally recognized as safe and effective,
			 not misbranded, and permitted to be marketed and sold in accordance with
			 all applicable rules and regulations for over-the-counter drugs.</text>
							</subparagraph>
              <subparagraph id="HD6FD3606758C44028D737A997C449089">
                <enum>(B)</enum>
                <text>In the case of a recommendation described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A/cl:ii" proposed="true">clause (ii) of such subsection</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug
			 Evaluation and Research</cato:entity-ref> shall issue a determination affirming or denying
			 the recommendation of the advisory committee, to be made publicly
			 available, within 45 days of receiving the recommendation, and inform the
			 sponsor that the sponsor must submit additional information to the
			 advisory committee in order to continue the review by the advisory
			 committee.</text>
							</subparagraph>
              <subparagraph id="HCBA801C7D00A49759827FEBDFF11E0A3">
                <enum>(C)</enum>
                <text>In the case of a recommendation described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:4/sp:A/cl:iii" proposed="true">clause (iii) of such subsection</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug
			 Evaluation and Research</cato:entity-ref> shall issue a determination affirming or denying
			 the recommendation of the advisory committee, to be made publicly
			 available, within 45 days of receiving such recommendation, and indicate
			 whether such sunscreen condition determined to be not generally recognized
			 as safe and effective to be marketed and sold unless an application with
			 respect to such condition is approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref>, or whether
			 additional data must be submitted to the advisory committee.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HE6FED2D20F9240BC965BC5491109D83E">
              <enum>(2)</enum>
              <header>Supervisory review of determination</header>
							<subparagraph id="H2B73354ABC9942B3BF14C742B348B45E">
                <enum>(A)</enum>
                <header>In general</header>
                <text>Any person may request a supervisory review of a determination of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Researchf" entity-parent-id="7524">Center for Drug Evaluation
			 and Research</cato:entity-ref> to not accept a recommendation of an advisory committee. Such
			 review may be conducted at the next supervisory or higher level above the
			 individual who made the determination.</text>
							</subparagraph>
              <subparagraph id="H1F7DD1930BFB4FCE878FE70323A8A639">
                <enum>(B)</enum>
                <header>Request for supervisory review</header>
                <text>A request described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:h/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be made to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than 30 days after
			 such decision and shall indicate in the request whether such person seeks
			 an in-person meeting or a teleconference. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall schedule an
			 in-person or teleconference review, if so requested, not later than 30
			 days after such request is made. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a decision to
			 the person requesting a review under this paragraph not later than 45 days
			 after the meeting.</text>
							</subparagraph>
              <subparagraph id="HADD50AF911CF484E8A9A759642DE2A39">
                <enum>(C)</enum>
                <header>Standard of supervisory review</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall be authorized to overturn a determination of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and
			 Research</cato:entity-ref> not to accept a recommendation of the advisory committee if the
			 supervisory review results in a decision by the reviewer that the
			 individual who made the determination did not provide reasonable and
			 sufficient substantive support for the decision to disregard the advisory
			 committee's recommendation.</text>
							</subparagraph>
              <subparagraph commented="no" id="H5F1448C2087D4EDA9330AAABD59F9AD2">
                <enum>(D)</enum>
                <header>Supervisory review decision</header>
                <text>If the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> overturns a determination by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Center for Drug Evaluation and Research" entity-parent-id="7524">Center for Drug Evaluation and Research</cato:entity-ref> not to
			 accept a favorable recommendation of an advisory committee, the
			 nonprescription sunscreen condition shall be generally recognized as safe
			 and effective, not misbranded, and permitted to be marketed and sold in
			 accordance with all applicable rules and regulations for over-the-counter
			 drugs.</text>
							</subparagraph>
              <subparagraph commented="no" id="H7B8849A6934F4AD28192EA760944F753">
                <enum>(E)</enum>
                <header>Final agency action</header>
                <text>A decision made through supervisory review shall constitute final agency action subject to judicial
			 review.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <subsection id="HB982DE22153C4929B217787B55BD945D">
            <enum>(j)</enum>
            <header>Reports</header>
						<paragraph id="HD2F4D0A9736245039B6FBA79D0C29D0B">
              <enum>(1)</enum>
              <header>In general</header>
              <text>Not later than 1 year after the date of enactment of the <short-title>
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation Act</cato:entity-ref>
                </short-title>, on March 1, 2015, and every 2 years thereafter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue a report to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref>
			 describing actions taken under this section.</text>
						</paragraph>
            <paragraph id="HC2A477C38EEA4C5390EAB89B2DE78180">
              <enum>(2)</enum>
              <header>Contents</header>
              <text>The reports under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:524B/ss:j/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall include—</text>
							<subparagraph id="H84BDE97090DB4784B5322D1E27BF13BD">
                <enum>(A)</enum>
                <text>a review of the progress made in issuing in a timely manner decisions on the safety and
			 effectiveness for sunscreen conditions for applications pending as of the
			 date of enactment of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation Act</cato:entity-ref>
                  </short-title>, including the number of pending applications—</text>
								<clause id="HE7C6C2F609FF4406A48C288B745ED44C">
                  <enum>(i)</enum>
                  <text>reviewed and the decision times for each application, measured from the date of original
			 eligibility application submission by the sponsor;</text>
								</clause>
                <clause id="HBD9A790AE74845AB843513EF9D642B7F">
                  <enum>(ii)</enum>
                  <text>resulting in a determination of generally recognized as safe and effective and not misbranded;</text>
								</clause>
                <clause id="H762175DE444245E19B75A7B25EFEF9B0">
                  <enum>(iii)</enum>
                  <text>resulting in a determination of not generally recognized as safe and effective and not misbranded
			 and the reasons for such determinations; and</text>
								</clause>
                <clause id="H57807CFDD9A74A19B61866E76A4DDA79">
                  <enum>(iv)</enum>
                  <text>for which a determination has not been made, an explanation for the delay, a description of the
			 current status of each such application, and the length of time such
			 applications have been pending, measured from the date of original
			 eligibility application submission by the sponsor;</text>
								</clause>
              </subparagraph>
              <subparagraph id="H4AD88DCF1C5F44C38D42D38F41C4FDF5">
                <enum>(B)</enum>
                <text>a review of the progress made in issuing in a timely manner a decision on safety and effectiveness
			 for sunscreen condition applications submitted after the date of enactment
			 of the <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Sunscreen Innovation Act" proposed="true">Sunscreen Innovation Act</cato:entity-ref>
                  </short-title>, including the number of such applications—</text>
								<clause id="H10774E92560842CFB903F9A2D3008156">
                  <enum>(i)</enum>
                  <text>reviewed and the decision times for each application;</text>
								</clause>
                <clause id="H4A2EBC88268941E7B1B51D1ED0B30D3A">
                  <enum>(ii)</enum>
                  <text>resulting in a determination of generally recognized as safe and effective and not misbranded; and</text>
								</clause>
                <clause id="H00AD647E1182426593A92C3BC03B2EDF">
                  <enum>(iii)</enum>
                  <text>resulting in a determination of not generally recognized as safe and effective and not misbranded
			 and the reasons for such determinations;</text>
								</clause>
              </subparagraph>
              <subparagraph id="H738C798FD7DC43939EAA09F6B1F1E125">
                <enum>(C)</enum>
                <text>a description of the staffing and resources relating to the costs associated with the review and
			 decisionmaking pertaining to applications;</text>
							</subparagraph>
              <subparagraph id="H888D3C7BF69E4F3A9E4486AE68A4CA28">
                <enum>(D)</enum>
                <text>a review of the progress in meeting the deadlines with respect to processing applications under
			 this section;</text>
							</subparagraph>
              <subparagraph id="H4C6932C331E04171B7F528622DFE7D08">
                <enum>(E)</enum>
                <text>to the extent the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines appropriate, recommendations for process improvements in the
			 handling of pending and new applications; and</text>
							</subparagraph>
              <subparagraph id="HFA512390E4534091AF2340D002AEE212">
                <enum>(F)</enum>
                <text>recommendations for expanding the applicability of this section to nonprescription active
			 ingredients or conditions that are not related to the sunscreen category
			 of over-the-counter drugs.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H28ADCBB1C5EB41EA9D91067E64F1664E">
              <enum>(3)</enum>
              <header>Method</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish the reports required under this subsection in the manner the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
			 determines to be the most effective for efficiently disseminating the
			 report, including publication of the report on the Internet website of the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection id="HFFCEF8D5474D436EB0F46868F3BE108F">
            <enum>(k)</enum>
            <header>Rules of construction</header>
						<paragraph id="HF73B3509170C4FB081980FEA64791F42">
              <enum>(1)</enum>
              <header>Authority to withdraw or suspend</header>
              <text>Nothing in this section shall be construed to alter the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary's</cato:entity-ref> authority to withdraw or
			 suspend from the market a drug that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines to be unsafe
			 or ineffective.</text>
						</paragraph>
            <paragraph id="H4D992ADEBBA34308855AED85E4135918">
              <enum>(2)</enum>
              <header>Other conditions</header>
              <text>Nothing in the section shall affect the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary's</cato:entity-ref> authority to review nonprescription conditions
			 other than sunscreen conditions.</text>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H00C2BB6F2245457D97DEE6800B669968">
      <enum>3.</enum>
      <header>Sunscreen testing and labeling</header>
      <text display-inline="no-display-inline">Not later than 180 days after the date of enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue
			 determinations with respect to—</text>
			<paragraph id="H9AEFC64E9D7F422A87F5781EB2A65B26">
        <enum>(1)</enum>
        <text display-inline="yes-display-inline">the appropriate testing and labeling requirements for sunscreens sold as an aerosol; and</text>
			</paragraph>
      <paragraph id="H27D12993EF6D4BA482C24B6A15218499">
        <enum>(2)</enum>
        <text display-inline="yes-display-inline">whether sunscreen may contain a label indicating a sun protection factor greater than 50.</text>
			</paragraph>
    </section>
  </legis-body>
</bill>
</doc>